A 90-day trial involving patients with Type I and Type II diabetes showed that Senseonics‘ (NYSE:SENS) implantable continuous glucose monitor was safe and accurate compared to reference glucose values, according to a study published in Diabetes Technology & Therapeutics.
The single-arm study enrolled 90 participants and implanted them with Senseonics’ Eversense device, which sends glucose data every five minutes to a transmitter. The transmitter then communicates that data to a mobile app, which displays the values in real-time. The system also includes alarms to warn the user if they’re approaching hyper- or hypoglycemia.
Get the full story at our sister site, Drug Delivery Business News.
The post Senseonics’ implantable glucose monitor succeeds in 90-day trial appeared first on MassDevice.
from MassDevice http://ift.tt/2EIXnjc
Cap comentari:
Publica un comentari a l'entrada